Revenue ($USD) : $13,305,000,000
R&D spend : not available
Employees : not available
Fiscal year end : 09/30/22
CEO : Tom Polen, chair, CEO and president; Mike Garrison, EVP and medical segment president; Richard Byrd, EVP and interventional segment president

Becton, Dickinson & Co.'s medical and interventional segments played an important role in the BD's Street-beating results for its quarter ended June 30, 2023.

Medical sales grew by 11.1% year-over-year in the quarter, and interventional increased 6.7%. The growth in the medical segment largely stemmed from robust performance in areas such as medication management and pharmaceutical solutions.

Meanwhile, advances in the interventional segment were due to improvements in surgery and peripheral intervention, as well as urology and critical care.

BD also recently achieved what CEO Tom Polen said was its No. 1 priority: FDA clearance of updated BD Alaris infusion systems. The clearance ended a hold on shipments of new Alaris systems that had been in place since a Class I recall in 2020.

Other recent BD news included the sale of its surgical instrumentation assets to Steris for $540 million and expanded availability of its PosiFlush SafeScrub syringe with an integrated disinfection unit.

(Note that we've added BD"s interventional segment to this year's ranking. The medical segment alone was No. 14 last year with nearly $9.5 billion in revenue.) –CN